Abstract
Hereditary gastric cancer includes the hereditary diffuse gastric cancer syndrome and a recently described syndrome designated as gastric adenocarcinoma and proximal polyposis of the stomach. Hereditary diffuse gastric cancer is caused by E-cadherin gene (CDH1) alterations and a model of development has been described, encompassing mild non-atrophic gastritis, in situ signet ring cell (diffuse) carcinoma, pagetoid spread of signet ring cells and invasive carcinoma. Gastric adenocarcinoma and proximal polyposis of the stomach is characterized by fundic gland polyposis, with areas of dysplasia or intestinal type gastric cancer, restricted to the proximal stomach, with no evidence of colorectal or duodenal polyposis or other heritable gastrointestinal cancer syndromes. The genetic cause of gastric adenocarcinoma and proximal polyposis of the stomach has not been identified yet.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- EGFR:
-
Epidermal Growth Factor Receptor
- FAP:
-
Familial Adenomatous Polyposis
- FDGC:
-
Familial Diffuse Gastric Cancer
- FGC:
-
Familial Gastric Cancer
- FGP:
-
Fundic Gland Polyposis
- GAPPS:
-
Gastric Adenocarcinoma and Proximal Polyposis of the Stomach
- HDGC:
-
Hereditary Diffuse Gastric Cancer
- IGCLC:
-
International Gastric Cancer Linkage Consortium
- MAP:
-
MYH-Associated Polyposis
- PJS:
-
Peutz–Jeghers Syndrome
- RTK:
-
Receptor Tyrosine Kinase
References
Avizienyte E, Frame MC (2005) Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymaltransition. Curr Opin Cell Biol 17:542–547. doi:10.1016/j.ceb.2005.08.007
Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC (2008a) Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 216:295–306. doi:10.1002/path.2426 (a)
Barber ME, Save V, Carneiro F, Dwerryhouse S, Lao-Sirieix P, Hardwick RH, Caldas C, Fitzgerald RC (2008b) Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 216:286–294. doi:10.1002/path.2415 (b)
Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P (2006) Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 4(262):275. doi:10.1016/j.cgh.2005.12.003
Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880
Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simões M (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687. doi:10.1002/path.1564
Carneiro F, Oliveira C, Suriano G, Seruca R (2008) Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer (HDGC). J Clin Pathol 61:25–30. doi:10.1136/jcp.2006.043679
Caron O, Schielke A, Svrcek M, Fléjou JF, Garzon J, Olschwang S, Sézeur A (2008) Usefulness of prophylactic gastrectomy in a novel large hereditary diffuse gastric cancer (HDGC) family. Am J Gastroenterol 103:2160–2161. doi:10.1111/j.1572 0241.2008.01982_17.x
Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53:814–820
Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92:181–187
Chung DC, Yoon SS, Lauwers GY, Patel D (2007) A women with a family history of gastric and breast cancer. N Engl J Med 357:283–291
Corso G, Roviello F, Paredes J, Pedrazzani C, Novais M, Correia J, Marrelli D, Cirnes L, Seruca R, Oliveira C, Suriano G (2007) Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol 33:1061–1067. doi:10.1016/j.ejso.2007.03.001
Crepaldi T, Pollack AL, Prat M, Zborek A, Mostov K, Comoglio PM (1994) Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol 125:313–320
Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C, International Gastric Cancer Linkage Consortium on behalf of the International Gastric Cancer Linkage Consortium (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444. doi:10.1136/jmg.2009.074237
Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD (2007) Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 11:142–147
Fujita H, Lennerz JK, Chung DC, Patel D, Deshpande V, Yoon SS, Lauwers GY (2012) Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1 mutated gastrectomies. Am J Surg Pathol 36(11):1709–1717. doi:10.1097/PAS.0b013e31826ca204
Gaya DR, Stuart RC, Going JJ, Stanley AJ (2008) Hereditary diffuse gastric cancer associated with E-cadherin mutation: penetrance after all. Eur J Gastroenterol Hepatol 20(12):1249–1251. doi:10.1097/MEG.0b013e328303df31
Gaya DR, Stuart RC, McKee RF, Going JJ, Davidson R, Stanley AJ (2005) E-cadherin mutation associated diffuse gastric adenocarcinoma: penetrance and nonpenetrance. Eur J Gastroenterol Hepatol 17:1425–1428
Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C (1998) Identification of germline E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58:4086–4089
Gionti E, Capasso O, Capasso O, Cancedda R (1983) The culture of chick embryo chondrocytes and the control of their differentiated functions in vitro. Transformation by rous sarcoma virus induces a switch in the collagen type synthesis and enhances fibronectin expression. J Biol Chem 258:7190–7194
Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26(16):17. doi:10.1038/79120
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405. doi:10.1038/32918
Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, Wiesner GL, Lindor NM, Burgart LJ, Toro TT, Lee D, Limacher JM, Shaw DW, Findlay MP, Reeve AE (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249–255. doi:10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2–9
Hackenson D, Edelman DA, McGuire T, Weaver DW, Webber JD (2010) Prophylactic laparoscopic gastrectomy for hereditary diffuse gastric cancer: a case series in a single family. JSLS 14(3):348–352. doi:10.4293/108680810X12924466007449
Hebbard PC, Macmillan A, Huntsman D, Kaurah P, Carneiro F, Wen X, Kwan A, Boone D, Bursey F, Green J, Fernandez B, Fontaine D, Wirtzfeld DA (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 16:1890–1895. doi:10.1245/s10434-009-0471-z
Hoschuetzky H, Aberle H, Kemler R (1994) Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127(1375):1380
Humar B, Guilford P (2008) Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. Future Oncol 4:229–239. doi:10.2217/14796694.4.2.229
Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P (2007) Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 67:2480–2489. doi:10.1158/0008-5472.CAN-06-3021
Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904–1909. doi:10.1056/NEJM200106213442504
Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG (2010) Pregnancy after prophylactic total gastrectomy. Fam Cancer 9:331–334. doi:10.1007/s10689-009-9316 y
Kluijt I, Siemerink EJ, Ausems MG, van Os TA, de Jong D, Simões-Correia J, van Krieken JH, Ligtenberg MJ, Figueiredo J, van Riel E, Sijmons RH, Plukker JT, van Hillegersberg R, Dekker E, Oliveira C, Cats A, Hoogerbrugge N, Dutch Working Group on Hereditary Gastric Cancer (2012) CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer 131(2):367–376. doi:10.1002/ijc.26398
Koea JB, Karpeh MS, Brennan MF (2007) Gastric cancer in young 524 patients: demographic, clinicopathological, and prognostic 525 factors in 92 patients. Ann Surg Oncol 7:346–351
La Vecchia C, Negri E, Franceschi S, Gentile A (1992) Family history and the risk of stomach and colorectal cancer. Cancer 70:50–55
Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130:612–619. doi:10.1067/msy.2001.117099
Lynch HT, Kaurah P, Wirtzfeld D, Rubinstein WS, Weissman S, Lynch JF, Grady W, Wiyrick S, Senz J, Huntsman DG (2008) Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112:2655–2663. doi:10.1002/cncr.23501
Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–376
Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, Luber B (2007) EGFR regulates RhoAGTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet 16:1639–1647. doi:10.1093/hmg/ddm113
Mateus AR, Simões-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G, Luber B, Seruca R (2009) E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 315:1393–1402. doi:10.1016/j.yexcr.2009.02.020
Newman EA, Mulholland MW (2006) Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 202:612–617. doi:10.1016/j.jamcollsurg.2005.12.017
Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879. doi:10.1097/01.sla.0000254370.29893.e4
Oelschlager BK, Yigit T, Kaufman JA, Pellegrini CA (2005) Hereditary diffuse gastric cancer. Med Gen Med 7:16
Oliveira C, Seruca R, Carneiro F (2006) Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 14:21–33
Oliveira C, de Bruin J, Nabais S, Ligtenberg M, Moutinho C, Nagengast FM, Seruca R, van Krieken H, Carneiro F (2004) Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in a HDGC tumour. Oncogene 23:2236–2240. doi:10.1038/sj.onc.1207335
Oliveira C, Moreira H, Seruca R, de Oliveira MC, Carneiro F (2005) Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. Virchows Arch 446:181–184. doi:10.1007/s00428-004-1156-4
Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D (2009a) Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18:1545–1555. doi:10.1093/hmg/ddp046
Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R (2009b) Quantification of epigenetic and genetic second hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 136:2137–2148. doi:10.1053/j.gastro.2009.02.065
Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS (2011) Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 149(3):347–355. doi:10.1016/j.surg.2010.07.005
Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23:1739–1748. doi:10.1038/sj.emboj.7600136
Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER (1999) Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8:607–610
Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Kingham K, Chun N, Ford JM, Longacre TA (2008) Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 32:799–809. doi:10.1097/PAS.0b013e31815e7f1a
Shaw D, Blair V, Framp A, Harawira P, McLeod M, Guilford P, Parry S, Charlton A, Martin I (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 54:461–468. doi:10.1136/gut.2004.049171
van Kouwen MC, Drenth JP, Oyen WJ, de Bruin JH, Ligtenberg MJ, Bonenkamp JJ, van Krieken JH (2004) Nagengast FM (2004) [18F]fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E cadherin mutation carrier. Clin Cancer Res 10:6456–6459. doi:10.1158/10780432.CCR-04-0599
Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG (1995) An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 32:942–945
Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027
Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S, Kaurah P, Shulkes A, Grimpen F, Clouston A, Moore D, Cullen D, Ormonde D, Mounkley D, Wen X, Lindor N, Carneiro F, Huntsman DG, Chenevix-Trench G, Suthers GK (2012) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61:774–779. doi:10.1136/gutjnl-2011-300348
Yanaru-Fujisawa R, Nakamura S, Moriyama T, Esaki M, Tsuchigame T, Gushima M, Hirahashi M, Nagai E, Matsumoto T, Kitazono T (2012) Familial fundic gland polyposis with gastric cancer. Gut 61:1103–1104. doi:10.1136/gutjnl-2011-301384
Yap AS, Kovacs EM (2003) Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol 160:11–16. doi:10.1083/jcb.200208156
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Carneiro, F. (2013). Pathology of Hereditary Gastric Cancer. In: Corso, G., Roviello, F. (eds) Spotlight on Familial and Hereditary Gastric Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6570-2_12
Download citation
DOI: https://doi.org/10.1007/978-94-007-6570-2_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6569-6
Online ISBN: 978-94-007-6570-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)